Octreotide has been an FDA-approved medication since the late 1980s, making it one of the longest-standing peptide drugs in routine clinical use, though it rarely comes up in conversations about newer research-chemical peptides. It's a useful example of what a mature, well-understood peptide therapy looks like.
What It Is
Octreotide is a synthetic analog of somatostatin, a hormone produced in the hypothalamus, pancreas, and gastrointestinal tract that acts as a broad inhibitory signal throughout the body, suppressing the release of numerous other hormones, including growth hormone, insulin, glucagon, and several gut hormones. Natural somatostatin has a half-life of only a few minutes, which makes it impractical as a drug; octreotide was engineered to retain somatostatin's receptor-binding activity while extending its half-life to roughly two hours (or, in its long-acting injectable formulation, weeks).
What It's FDA-Approved to Treat
Octreotide's approved uses center on conditions involving hormone overproduction. It's used to treat acromegaly (a condition of excess growth hormone, usually from a pituitary tumor) in patients who haven't responded adequately to surgery or radiation, and to treat symptoms, like severe diarrhea and flushing, caused by hormone-secreting tumors such as carcinoid tumors and VIPomas. It's also used in some settings to reduce complications after pancreatic surgery and to help control bleeding from esophageal varices, enlarged veins in the esophagus that can occur with severe liver disease.
How It Compares to Growth Hormone Peptides
Octreotide's relationship to growth hormone is essentially the opposite of the growth hormone secretagogues covered elsewhere on this site, like sermorelin, CJC-1295, and the GHRPs. Where those compounds are designed to stimulate growth hormone release, octreotide suppresses it. That makes it a treatment for growth hormone excess (acromegaly), not a tool for raising growth hormone levels, and it's not used or marketed for anti-aging, muscle-building, or fat-loss purposes the way secretagogues often are.
The Evidence Base
As an FDA-approved drug with decades of clinical use, octreotide's evidence base includes placebo-controlled human trials supporting each of its approved indications, along with a long real-world safety record that gives prescribers a clear picture of its side-effect profile, unlike the animal-only evidence base behind many unapproved research peptides discussed elsewhere on this site.
Safety Considerations
Octreotide's most common side effects involve the gastrointestinal tract, including nausea, abdominal cramping, and diarrhea, since it directly suppresses gut hormone signaling. Longer-term use is associated with an increased risk of gallstones, because somatostatin suppression reduces gallbladder contraction. Because it also suppresses insulin and glucagon, it can affect blood sugar control in either direction, and people with diabetes using octreotide typically need closer glucose monitoring.
The Bottom Line
Octreotide is a well-established, narrowly targeted hormone-suppressing peptide drug, not a wellness or performance compound. It illustrates how differently peptide hormones can be used depending on which direction of a signaling pathway a condition calls for: suppressing hormone excess rather than stimulating a deficiency. It's prescribed and monitored by specialists, typically endocrinologists or gastroenterologists, managing a specific diagnosed condition, and isn't something to use or seek out outside of that context.